
Haemonetics Corporation (HAE)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
85.42 - Open
84.58 - Bid 84.29 x 10000
- Ask 84.49 x 20000
- Day's Range
83.47 - 84.68 - 52 Week Range
47.32 - 87.32 - Volume
251,908 - Avg. Volume
894,906 - Market Cap (intraday)
3.82B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
41.01 - EPS (TTM)
2.05 - Earnings Date Aug 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
86.60
Recent News
View MorePerformance Overview
Trailing total returns as of 7/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
Market Cap
3.88B
Enterprise Value
4.86B
Trailing P/E
41.67
Forward P/E
16.37
PEG Ratio (5yr expected)
1.36
Price/Sales (ttm)
3.03
Price/Book (mrq)
4.87
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
18.11
Financial Highlights
Profitability and Income Statement
Profit Margin
7.29%
Return on Assets (ttm)
6.49%
Return on Equity (ttm)
12.03%
Revenue (ttm)
1.33B
Net Income Avi to Common (ttm)
97.31M
Diluted EPS (ttm)
2.05
Balance Sheet and Cash Flow
Total Cash (mrq)
246.26M
Total Debt/Equity (mrq)
160.08%
Levered Free Cash Flow (ttm)
298.09M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports
View MoreRaising target price to $87.00
Haemonetics Corp has an Investment Rating of HOLD; a target price of $87.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $82.00
Haemonetics Corp has an Investment Rating of HOLD; a target price of $82.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $78.00
Haemonetics Corp has an Investment Rating of HOLD; a target price of $78.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about HAE?
Haemonetics Corp has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target









![[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://cdn.statically.io/img/s.yimg.com/uu/api/res/1.2/JDc8Q43tjkZAOscxTVa7kA--~B/Zmk9c3RyaW07aD02Mzt3PTg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp)